Submitted by Camila Magrini da Silva (camilamagrini@hotmail.com) on 2017-06-07T13:42:16Z No. of bitstreams: 1 DISSERTAÇÃO FINAL CORREÇÃO BIBLIOTECA.pdf: 972605 bytes, checksum: 2942eb701eed7cc3e83b5f8f93af8361 (MD5) / Rejected by Luiz Galeffi (luizgaleffi@gmail.com), reason: Solicitamos que realize uma nova submissão seguindo a orientação abaixo: O arquivo submetido não contém os nomes da composição da banca examinadora. Corrija esta informação e realize uma nova submissão com o arquivo correto. Agradecemos a compreensão. on 2017-06-07T13:55:27Z (GMT) / Submitted by Camila Magrini da Silva (camilamagrini@hotmail.com) on 2017-06-07T14:15:27Z No. of bitstreams: 1 DISSERTAÇÃO FINAL CORREÇÃO BIBLIOTECA.pdf: 972605 bytes, checksum: 2942eb701eed7cc3e83b5f8f93af8361 (MD5) / Rejected by Luiz Galeffi (luizgaleffi@gmail.com), reason: Solicitamos que realize uma nova submissão seguindo a orientação abaixo: O arquivo submetido não contém os nomes da composição da banca examinadora. Corrija esta informação e realize uma nova submissão com o arquivo correto. Agradecemos a compreensão. on 2017-06-07T14:29:24Z (GMT) / Submitted by Camila Magrini da Silva (camilamagrini@hotmail.com) on 2017-06-07T15:06:21Z No. of bitstreams: 1 DISSERTAÇÃO FINAL MEMBROS BANCA.pdf: 924381 bytes, checksum: 8d8e933d81b027145a10523dd51ba0b5 (MD5) / Approved for entry into archive by Luiz Galeffi (luizgaleffi@gmail.com) on 2017-06-07T16:10:49Z (GMT) No. of bitstreams: 1 silva_cm_me_fran.pdf: 924381 bytes, checksum: 8d8e933d81b027145a10523dd51ba0b5 (MD5) / Made available in DSpace on 2017-06-07T16:10:49Z (GMT). No. of bitstreams: 1 silva_cm_me_fran.pdf: 924381 bytes, checksum: 8d8e933d81b027145a10523dd51ba0b5 (MD5) Previous issue date: 2016-10-31 / O sistema de saúde privado consiste em uma clássica alternativa utilizada pelo Estado para atender a prestação e a concretização dos serviços à saúde. A contratação do sistema de saúde privado não proíbe o cidadão de acessar e utilizar o sistema de saúde público, pois esse tem direito ao acesso universal à saúde, previsto na Constituição Federal. Esse direito universal é uma conquista social a qual não se pretende pesquisar, pois as pretensões são: averiguar as razões que conduzem o cidadão a realizar a contratação do sistema de saúde privado, e, ainda, utilizar o sistema de saúde público?; averiguar se o sistema de saúde privado realiza o ressarcimento integral do uso do sistema de saúde público?; averiguar se a Agência Nacional de Saúde Suplementar (ANS) realiza, de forma efetiva, a regulação da relação do sistema de saúde privado? Essas averiguações permeiam algumas das competências da ANS previstas na Lei n. 9.961/2000, as quais devem servir de ferramentas na promoção de políticas públicas regulatórias para fomentar a efetividade dos direitos à saúde. O descumprimento a essas competências pode ocasionar problemas regulatórios, e, gerar à judicialização da regulação da saúde. A metodologia utilizada nesta investigação foi a teórico-dedutiva combinada com dados empíricos. / The private health system consists of a classic alternative used by the State to meet the delivery and delivery of health services. The contracting of the private health system does not prohibit citizens from accessing and using the public health system, since they have the right to universal access to health, as provided for in the Federal Constitution. This universal right is a social achievement that is not intended to be researched, since the pretensions are: to investigate the reasons that lead the citizen to contract the private health system, and also to use the public health system? To investigate whether the private health system provides full compensation for the use of the public health system? To investigate whether the National Supplementary Health Agency effectively regulates the relationship of the private health system? These inquiries pervade some of the competencies of National Supplementary Health Agency provided for in Law n. 9.961/2000, which should serve as tools in the promotion of public regulatory policies to promote the effectiveness of health rights. Noncompliance with these competencies may lead to regulatory problems, and, to the judicialization of health regulation. The methodology used in this research was theoretical-deductive combined with empirical data.

Submitted by Sérgio Ricardo Nutti Marangoni (marangoni@smabr.com) on 2015-09-24T19:30:25Z No. of bitstreams: 1 Dissertação Versão Final Pós Banca 21.09.2015 com ficha catolográfica.pdf: 1084907 bytes, checksum: 896ccda8e74792ad7d1b30584207558e (MD5) / Rejected by Renata de Souza Nascimento (renata.souza@fgv.br), reason: Sérgio, boa tarde Conforma normas da ABNT, para que possamos aceitar seu trabalho junto à biblioteca, será necessário alguns ajustes: Tamanho da fonte 12 Na capa, retirar a formatação em negrito; retirar a acentuação de Getúlio. Nos agradecimentos, retirar os espaços que constam entre os parágrafos. Em seguida, submeter novamente o trabalho. grata. on 2015-09-24T19:41:52Z (GMT) / Submitted by Sérgio Ricardo Nutti Marangoni (marangoni@smabr.com) on 2015-09-24T21:26:05Z No. of bitstreams: 1 Dissertação Versão Final Pós Banca 24.09.2015 com ficha catolográfica e ajustes FGV.pdf: 1437690 bytes, checksum: 03178919a79fc12485d0e1ff0bbf0447 (MD5) / Rejected by Renata de Souza Nascimento (renata.souza@fgv.br), reason: Sérgio, só mais um detalhe que não me atentei anteriormente. Retire a sigla FGV que consta ao lado do nome da Fundação (na capa). Você submetendo, imediatamente já aprovo. Obrigada. on 2015-09-24T21:31:10Z (GMT) / Submitted by Sérgio Ricardo Nutti Marangoni (marangoni@smabr.com) on 2015-09-24T21:50:28Z No. of bitstreams: 1 Dissertação Versão Final de Submissão - 24.09.15.pdf: 1442767 bytes, checksum: 826fe73c9d6a7707be6bb531fbb69bbf (MD5) / Approved for entry into archive by Renata de Souza Nascimento (renata.souza@fgv.br) on 2015-09-24T21:51:26Z (GMT) No. of bitstreams: 1 Dissertação Versão Final de Submissão - 24.09.15.pdf: 1442767 bytes, checksum: 826fe73c9d6a7707be6bb531fbb69bbf (MD5) / Made available in DSpace on 2015-09-24T21:58:23Z (GMT). No. of bitstreams: 1 Dissertação Versão Final de Submissão - 24.09.15.pdf: 1442767 bytes, checksum: 826fe73c9d6a7707be6bb531fbb69bbf (MD5) Previous issue date: 2015-08-27 / The Right to Dissent and Appraisal and reimbursement amounts should be interpreted together. They are two sides of the same coin. The measurement of the reimbursement amount, as foreseen by Law 6404/1976, article 45 and its paragraphs is not necessarily made according to the value of the company’s net assets. These only establish a minimum amount, in case the company by-laws or articles of association provide such minimum amount. In case it does not, there is a void as to the criterion to establish the reimbursement amount. The best interpretation is the systematic and purposeful one of the law, in the sense that the value of the shares to be reimbursed should be the closest possible to their actual amount. Currently, in the majority of the cases, the economic value is the one that best represents the actual value of a company and therefore, in case of a void in the by-laws or articles of association, this criterion should prevail to calculate the reimbursement amount. The concept and function of the right to dissent and appraisal in companies, its characteristics, mainly the exhaustive character of its hypotheses and the possibility of reverting the decision motivating the dissent and appraisal, its legislative background, mainly the political and economic influences in the definition of its hypothesis, serve as basis for this rationale. As supporting elements, the paper also analyzes the court precedents and jurisprudence and addresses the understanding of the 'Comissão de Valores Mobiliários' (Brazilian SEC). As a further means to justify and base the rationale developed in the present paper, the efficiency and fair value concepts and their possible and pacific coexistence are addressed on the item dealing with a view of the Law and Economics on this issue. Finally, through the analysis of all the articles of incorporation and by-laws of the companies listed at the 'BMF/BOVESPA' on the first half of January 2015, an analysis is provided as how in practice stock companies have dealt with this issue. / Direito de recesso e valor de reembolso em companhias devem ser interpretados conjuntamente. São duas faces da mesma moeda. A aferição do valor de reembolso, conforme previsto no artigo 45 e respectivos parágrafos da Lei 6.404/1976, não é necessariamente feita pelo valor de patrimônio líquido da companhia. Ali se estabelece apenas um piso, no caso de previsão estatutária sobre o tema. No caso de silencia estatutário, há uma lacuna quanto ao critério de aferição do valor de reembolso. A melhor interpretação é uma interpretação sistemática e finalística da norma, no sentido de que o valor das ações a serem reembolsadas deve ser o valor mais próximo do real. Atualmente, na maioria dos casos, o valor econômico é o que melhor representa o real valor de uma companhia e, portanto, em caso de silencia estatutário, deveria prevalecer como critério de aferição do valor de reembolso. Como fundamentos deste raciocínio, utiliza-se do conceito e função do direito de recesso em companhias, suas características, principalmente a taxatividade de suas hipóteses e possibilidade de reversão da decisão motivadora do recesso, seu histórico legislativo, mormente as influências políticas e econômicas na definição de suas hipóteses. O trabalho analisa, também, como seu elemento de sustentação, a jurisprudência e aborda o entendimento da Comissão de Valores Mobiliários. Ainda como forma de justificar e fundamentar o raciocínio desenvolvido no presente trabalho, os conceitos de eficiência e valor justo e sua possível e pacífica convivência são abordados no item que trata de uma visão de Direito e Economia sobre o tema. Por fim, faz-se uma análise de como, na prática, as companhias de capital aberto tem se comportado com relação a esta questão, por meio da análise de todos os estatutos das companhias listadas na 'BMF/BOVESPA' na primeira quinzena de janeiro de 2015.

Submitted by Cristiane Shirayama (cristiane.shirayama@fgv.br) on 2011-05-24T14:04:32Z No. of bitstreams: 1 61090100004.pdf: 892202 bytes, checksum: ddb115acbf78277c0e1537167151923c (MD5) / Approved for entry into archive by Gisele Isaura Hannickel(gisele.hannickel@fgv.br) on 2011-05-24T14:10:18Z (GMT) No. of bitstreams: 1 61090100004.pdf: 892202 bytes, checksum: ddb115acbf78277c0e1537167151923c (MD5) / Approved for entry into archive by Gisele Isaura Hannickel(gisele.hannickel@fgv.br) on 2011-05-24T14:10:58Z (GMT) No. of bitstreams: 1 61090100004.pdf: 892202 bytes, checksum: ddb115acbf78277c0e1537167151923c (MD5) / Made available in DSpace on 2011-05-24T14:20:04Z (GMT). No. of bitstreams: 1 61090100004.pdf: 892202 bytes, checksum: ddb115acbf78277c0e1537167151923c (MD5) Previous issue date: 2011-02-28 / The need to restrain the lack of control of the health plan market became an important issue in the national scene in the 90s. Thus, 10 years after the Unified Health System's (SUS) creation, in a context of pressure and of low health plan regulation, the Law nº 9.656/1998 was instituted. It was an unprecedented legislation in Brazil because it regulated the activities of health service companies (OPS) at national level. Among other issues, the Law established the SUS reimbursement policy, imposing in the Article nº 32 that when a beneficiary uses the public system for a procedure which is covered by his or her health plan, the OPS should reimburse the SUS. However, this policy is one of the conflicts that lie within the limits of interests between the private and public sector: already in 1998 OPSs filed an unconstitutional act against the policy and they resort to lawsuits for not paying the public coffers. Even after 12 years of the Law's creation, it is still unknown the real impact of Article nº 32 on its target public, therefore, this study aimed to evaluate the effectiveness of the SUS reimbursement policy. The methodology used was based on the evaluation of data managed by the Supplementary Health National Agency (ANS) and the Ministry of Health / DATASUS, and of interviews performed with managers of the public and the private sector. Despite ANS’s efforts, the results showed reduced effectiveness of the policy in financial and legal terms; and on its target public. Only 22% of what ANS charged returned to the Unified System from 1999 to 2006, the policy is viewed as unconstitutional by the market and has little impact over OPSs, SUS and beneficiaries. Issues such as the values of the national unified equivalence procedure table (TUNEP), the reimbursement’s unconstitutionality and the beneficiary’s own option to use SUS’s services were voiced by health plan managers as factors that generate OPSs’s resistance towards the policy. Public actors affirmed its importance for beneficiary and SUS protection, and the fact that made possible the construction of the Registry of Beneficiaries of all OPSs. On the other hand, they recognize the policy’s poor results. It is recommended to maintain the SUS reimbursement policy as a tool to deter companies which have the intention to bypass the legal requirements of the Regulatory Agency, that acts promoting the public interest in supplementary health care. However, it must undergo the necessary reformulations and consensus must be established between the Unified System and the supplementary sector. / A necessidade de coibir o descontrole do mercado dos planos de saúde tornou-se uma questão importante no cenário nacional, na década de 90. Desta forma, 10 anos após a criação do Sistema Único de Saúde (SUS), em um contexto de pressões e de baixa regulação dos planos de saúde, instituiu-se a Lei no 9.656/1998, uma legislação inédita no Brasil, pois regulou as atividades das operadoras de planos de saúde (OPSs) em nível nacional. Dentre outras questões, a Lei estabeleceu a política de ressarcimento ao SUS, impondo no Artigo no 32 o ressarcimento pelas OPSs das despesas geradas ao SUS quando um beneficiário usa a rede pública para um procedimento coberto pelo seu plano. No entanto, esta política é parte dos conflitos que se situa no limite dos interesses entre o setor privado e público: as OPSs já em 1998 moveram uma ação direta de inconstitucionalidade contra a mesma e têm recorrido frequentemente ao judiciário para não pagarem os valores cobrados pela Agência Nacional de Saúde Suplementar (ANS). Após 12 anos da Lei, ainda não se conhece o seu real impacto. Portanto, o presente trabalho teve como objetivo avaliar a efetividade da política de ressarcimento ao SUS. A metodologia utilizada baseou-se na avaliação de dados produzidos pela ANS e pelo Ministério da Saúde/DATASUS, e das entrevistas realizadas com gerentes da rede pública e privada. Apesar das ações da ANS, os resultados apontaram a reduzida efetividade da política em termos financeiros, jurídicos e sobre o seu público-alvo. Apenas 22% do cobrado às OPSs foi restituído ao Sistema Único de 1999 a 2006, a política é vista como inconstitucional pelo mercado e tem reduzido impacto sobre as OPSs, o SUS e os beneficiários. Questões como os valores da tabela única nacional de equivalência de procedimentos (TUNEP), a inconstitucionalidade do ressarcimento e a opção do beneficiário pelo uso do SUS foram explicitadas pelos gestores de planos de saúde como fatores geradores de resistência das OPSs frente à política. Os dirigentes públicos afirmaram a importância da mesma para tutela de beneficiários e do SUS, como de ter viabilizado a construção do Cadastro de Beneficiários da ANS, porém, reconhecem os seus baixos resultados. Recomenda-se a manutenção do ressarcimento ao Sistema Único como um instrumento para coibir empresas que procuram contornar as exigências legais da Agência Reguladora, a qual atua promovendo a defesa do interesse público na assistência suplementar à saúde. No entanto, a mesma deve sofrer as devidas reformulações e devem ser estabelecidos consensos entre o SUS e o setor suplementar.

Made available in DSpace on 2016-06-02T18:57:46Z (GMT). No. of bitstreams: 1 5208.pdf: 2271698 bytes, checksum: e63b45cd9f9faaf6ec3c98a0684e7871 (MD5) Previous issue date: 2013-03-27 / Fundação Ford / This research examines the implementation of agricultural projects benefited from the District Development Fund (FDD), taking as if the District of Chibuto, Mozambique. Considering the characteristics of the country, the relevance of the FDD and the need to have a higher rate of payment of these projects highlights the need to study these projects, despite their increased over the years, has led to low rates compared financial resources to pay the FDD. Therefore, compromises the multiplier effect of these financial resources that should benefit more community development projects. For the preparation of this paper was applied to semi-structured interview managers FDD District and the methodology was used "snowball" in the selection of farmers interviewed, where the inclusion of informants was progressive as one respondent indicated behalf of another interviewee. Applied questionnaire with closed and open questions about the implementation of the projects. It was found that most farmers and agricultural associations are delinquent on the payment of the FDD, even with money incomes satisfactory and that some aspects of technical, institutional and human influence in the payment of the FDD. It is imperative to recast the management mechanisms FDD accompanied by other public policies. / O presente trabalho analisa a implementação de projetos agrícolas beneficiados pelo Fundo Distrital de Desenvolvimento (FDD), tomando como caso o Distrito de Chibuto, Moçambique. Considerando as características do país, a relevância do FDD e a necessidade de se ter uma maior taxa de pagamento desses projetos, destaca-se a necessidade do estudo desses projetos. Apesar de seu aumento ao logo dos anos, a taxa de adimplência do pagamento dos recursos financeiros do FDD é baixa o que compromete o efeito multiplicador desses recursos financeiros que deveriam beneficiar mais projetos de desenvolvimento comunitário. Para a elaboração do trabalho foi aplicada entrevista semi-estruturada aos gestores do FDD do Distrito e foi usada a metodologia bola de neve na seleção dos agricultores entrevistados, onde a inclusão de informantes foi progressiva à medida que um entrevistado indicou nome de outro entrevistado. Aplicou-se questionário contendo perguntas fechadas e abertas sobre a implementação dos projetos. Constatouse que a maioria dos agricultores familiares e associações agrícolas estão inadimplentes em relação ao pagamento do FDD, mesmo com rendas monetárias satisfatórias e que alguns fatores de natureza técnica, institucional e humano influenciam no pagamento do FDD. É imperativa a necessidade de reformulação dos mecanismos de gestão do FDD acompanhada de outras políticas públicas.

This master thesis analyses factors that determine the prices of prescription medicine. The theoretical part is outlining the fundamentals of pharmaceutical market, identifying the main price components and determinants with main focus on pricing and reimbursement policies in the world. The empirical part is dedicated to the pharmaceutical market in the Czech Republic. It explores the impact of state regulatory measures such as internal and external reference pricing on the prescription medicine prices. A regression analysis was conducted to determine what factors have significant impact on the prices. Furthermore a t-test was performed to discover differences in price levels between regulated and unregulated drugs as well as between originator medicine and generics.

The influence of globalization is strengthening in all markets including the insurance market. In the past few years, new trends are bringing out various changes. People are becoming aware of the risks associated by not being covered by insurance and the exposure of financial loss that they could face. Due to this awareness, there are more questions that need to be raised by the insurer. Are the clients being provided enough coverage? What types of criteria should be set? All these questions are being asked by the insurance provider in order to alleviate any problems/loss and identify all the risks up front in order to prepare for these possible scenarios. Most people in the Czech Republic are becoming more aware of the bad current situation of the social system. Therefore, more people are coming to private financial insurance consultants. Life insurance have experienced many changes the past 10 years in which it is now able to offer the same complex coverage as in rich western countries. Clients are now looking for variety and flexibility. The question is how to set up these products correctly? I have been involved in professional insurance for the past several years and have developed methodical guidelines using both my knowledge and experience aimed at helping these clients be covered for these unforeseen circumstances and protect their finances.

Clinical practice guidelines (CPGs) are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options. CPGs’ recommendations have traditionally focused on informing clinicians and patients on the best options, i.e., supporting decisions that occur at the clinical encounter level. Considering all their advantages (a systematic and comprehensive review of the evidence, a multidisciplinary team assessing the evidence and balancing benefits and harms, and the additional considerations such as patients’ preferences, implementability and feasibility of interventions and their costs) CPGs have also become powerful tools to inform decisions and activities outside the clinical encounter. This, because the clinical encounter cannot be completely separated from other decisions that indirectly affect that level, such as those related to quality improvement activities and economic decisions in healthcare. Moreover, activities that are not directly related to the clinical encounter can benefit from CPGs, like education and licensing activities and research prioritization processes, or judicial decisions. The role of CPGs in all these activities has been neglected in the literature. In this study, I performed a critical interpretive synthesis of the literature to summarize the different roles CPGs play outside the clinical encounter and to understand how, and under what conditions CPGs are used in these roles. I also conducted an international survey to describe how frequent these roles exist, from the CPGs developers' perspectives. Lastly, I conducted a multiple case study to understand how and under what conditions CPGs play one of the main roles outside the clinical encounter (drug funding decisions), in two different settings (Colombia and Canada/Ontario). Based on the results, I developed a framework to describe and categorize the roles of CPGs outside the clinical encounter and to determine how and under what conditions CPGs are used in these roles. I highlighted the key areas that require additional methodological research and categorize the roles in main, secondary and unanticipated roles. I also described how international developers reported that CPGs play these roles and how these roles are part of their CPGs final aims in the second study. Lastly, in the case study, I revealed that CPGs were instrumentally used to inform one of the main roles, drug funding decisions, in the Colombian case, and they had a minor conceptual use in the case of Canada/Ontario. / Thesis / Doctor of Philosophy (PhD)

No description available.

Expropriation används för att med tvång ta mark i anspråk för att tillgodose allmänna behov. Bestämmelserna kring detta återfinns i expropriationslagen (SFS 1972:719) där det specificeras vem som får expropriera, hur det går till, vilka ersättningsmöjligheter som finns m.m. Lagen var i princip oförändrad sedan dess införande i början av 1970-talet och 2005 tillsattes på uppdrag av regeringen en grupp för att utvärdera reglerna. Syftet var att stärka äganderätten och resultatet blev huvudsakligen ändringar av tre bestämmelser, schablonpåslaget, toleransavdraget och presumtionsregeln.  Denna uppsats har som syfte att besvara frågan om varför det finns tvångsmöjligheter och hur detta går till. Vidare utvärderas också det aktualiserade ändringarna från 2010 och slutsatser dras kring deras påverkan på annan rätt, oklarheter och om de kan anses uppnå syftet med lagändringen. För att besvara dessa frågor baseras uppsatsen på existerande lagtext, förarbeten och annan juridisk text. Till hjälp används även relevant litteratur inom det markjuridiska området. Utöver detta så har även det svenska ersättningssystemet jämförts mot internationell rätt via ett par utvalda länder i Europa.  Slutsatser som kan dras är att lagändringarna huvudsakligen är positiva och tjänar det syfte som ursprungligen satts upp av de som är ansvariga för ändringarna. Dock finns vissa problem med lagstiftningen, såsom oklarheter i värdering och definitioner, inte helt kompletta följdändringar i andra lagar eller oförutsedda konsekvenser. Ändringarna i ersättningen av marknadsvärdet till ett högre värde än tidigare är den klart största förändringen och i jämförelse mot internationell rätt så har Sverige bland de mest generösa ersättningsreglerna. Vissa länder har börjat anpassa sin lagstiftning enligt samma principer som föranledde förändringar i den svenska lagstiftningen men har ännu inte nått lika långt. Detta kan vi troligtvis ses förändras inom den närmsta framtiden då individens rättigheter kommer i fokus samt att expropriation numera ofta används för andra ändamål än förr. / Expropriation (also known as compulsory purchase or eminent domain) is the method used for acquiring land by force to cater public needs. The regulations regarding this is in Swedish law is found in the Expropriation Act (SFS 1972:719) where it is specified who may use expropriation, how it works, how the compensation is decided, etc. The law has been mostly unaltered since its adaptation in the early 1970’s and in 2005 a group was assigned to investigate possible changes. This was to achieve the purpose of strengthening individual and ownership rights and resulted in three main changes. Firstly, the land compensation was raised from 100 % of the market value to 125 %, secondly a special tolerance deduction was removed, and thirdly the rule of presumption was also removed. This thesis aims to answer the question of why there are compulsory measures and how they work. It will also examine the changes to the Swedish expropriation act from 2010 to evaluate how it affected other parts of the justice system, what could be unclear and whether they achieved their own purpose. To answer this, existing legislation has been used, as well as its preparatory work and other legal documents. Furthermore, other relevant legal documents have been reviewed. A brief investigation into other international legal systems has also been conducted. In summary we can draw conclusions regarding these amendments and see that they are mainly positive and serves the purpose behind the changes. There are however certain problems with the legislation, such as difficulties with the valuation and definitions, certain follow-up changes to other legislation and some unforeseen consequences. The raised compensation for market value was the clearly biggest change and in comparison to international law, the compensation regulations in Sweden is among the most liberal. Some countries have begun altering their respective laws in accordance with the same principles used for the Swedish amendments but have yet to reach the levels that has been adapted here. This is probably something that will change further in the near future as individual rights are more in focus and because expropriation these days is used for different purposes than before.

No description available.